Long-term Consequences of COVID-19: Chemosensory Disorders
Purpose of Review A number of sequelae after acute coronavirus disease 2019 (COVID-19) significantly affect the quality of life of patients. The chemosensory disorders including olfactory dysfunction (OD) and gustatory dysfunction (GD) are two of the commonest symptoms complained by patients with COVID-19. Although chemosensory function has been reported improved in over 60% of COVID-19 patients in a short time after acute infection, it may last as a major symptom for patients with long COVID-19. This narrative review discussed current literatures on OD and GD in long COVID-19 including the prevalence, risk factors, possible mechanisms, and potential therapies. Recent Findings Although the prevalence of OD and GD has declined continuously after acute COVID-19, a considerable number of patients had persistent chemosensory disorders 3 months to 2 years after symptom onset. Female gender, initial severity of dysfunction, nasal congestion, emotional distress and depression, and SARS-CoV-2 variants have been identified as risk factors for persistent OD and GD in long COVID-19. The pathogenesis of OD and GD in long COVID-19 remains unknown, but may be analogous to the persistent OD and GD post common respiratory viral infection. Corticosteroids and olfactory training might be a potential choice regarding the treatment of lasting OD and GD after SARS-CoV-2 infection; however, more studies are needed to prove it. Summary OD and GD are common long-term consequences of COVID-19 and influenced by gender, initial severity of dysfunction, emotional distress and depression, and SARS-CoV-2 variants. More studies are needed to illustrate their pathogenesis and to establish therapeutic strategies..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
---|---|
Enthalten in: |
Current allergy and asthma reports - 23(2022), 2 vom: 27. Dez., Seite 111-119 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Liao, Bo [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
Gustatory dysfunction |
---|
Anmerkungen: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
---|
doi: |
10.1007/s11882-022-01062-x |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR04929038X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR04929038X | ||
003 | DE-627 | ||
005 | 20230519172448.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230210s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s11882-022-01062-x |2 doi | |
035 | |a (DE-627)SPR04929038X | ||
035 | |a (SPR)s11882-022-01062-x-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Liao, Bo |e verfasserin |4 aut | |
245 | 1 | 0 | |a Long-term Consequences of COVID-19: Chemosensory Disorders |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
520 | |a Purpose of Review A number of sequelae after acute coronavirus disease 2019 (COVID-19) significantly affect the quality of life of patients. The chemosensory disorders including olfactory dysfunction (OD) and gustatory dysfunction (GD) are two of the commonest symptoms complained by patients with COVID-19. Although chemosensory function has been reported improved in over 60% of COVID-19 patients in a short time after acute infection, it may last as a major symptom for patients with long COVID-19. This narrative review discussed current literatures on OD and GD in long COVID-19 including the prevalence, risk factors, possible mechanisms, and potential therapies. Recent Findings Although the prevalence of OD and GD has declined continuously after acute COVID-19, a considerable number of patients had persistent chemosensory disorders 3 months to 2 years after symptom onset. Female gender, initial severity of dysfunction, nasal congestion, emotional distress and depression, and SARS-CoV-2 variants have been identified as risk factors for persistent OD and GD in long COVID-19. The pathogenesis of OD and GD in long COVID-19 remains unknown, but may be analogous to the persistent OD and GD post common respiratory viral infection. Corticosteroids and olfactory training might be a potential choice regarding the treatment of lasting OD and GD after SARS-CoV-2 infection; however, more studies are needed to prove it. Summary OD and GD are common long-term consequences of COVID-19 and influenced by gender, initial severity of dysfunction, emotional distress and depression, and SARS-CoV-2 variants. More studies are needed to illustrate their pathogenesis and to establish therapeutic strategies. | ||
650 | 4 | |a Olfactory dysfunction |7 (dpeaa)DE-He213 | |
650 | 4 | |a Gustatory dysfunction |7 (dpeaa)DE-He213 | |
650 | 4 | |a Recovery |7 (dpeaa)DE-He213 | |
650 | 4 | |a Long COVID-19 |7 (dpeaa)DE-He213 | |
700 | 1 | |a Deng, Yi-Ke |4 aut | |
700 | 1 | |a Zeng, Ming |4 aut | |
700 | 1 | |a Liu, Zheng |0 (orcid)0000-0002-4168-6702 |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Current allergy and asthma reports |d Heidelberg [u.a.] : Springer, 2001 |g 23(2022), 2 vom: 27. Dez., Seite 111-119 |w (DE-627)SPR022844430 |w (DE-600)2094153-5 |x 1534-6315 |7 nnns |
773 | 1 | 8 | |g volume:23 |g year:2022 |g number:2 |g day:27 |g month:12 |g pages:111-119 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11882-022-01062-x |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |d 23 |j 2022 |e 2 |b 27 |c 12 |h 111-119 |